ASX Announcement

VIRALEZE™ to relaunch in the UK

- **VIRALEZE™ will relaunch in the UK following successful resolution of issues raised by the UK regulator, MHRA**
- **Relaunch preparations are already underway and VIRALEZE™ is expected to be available to UK consumers in the coming weeks**
- **The product is expected to be available both online and through LloydsPharmacy stores**

Melbourne, Australia; 1 April 2022: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it has successfully resolved the queries raised last year by the UK Medicines and Healthcare products Regulatory Agency (MHRA), clearing the way for the relaunch of VIRALEZE™ in the UK as soon as possible.

In June 2021, sales and promotion of VIRALEZE™ in the UK were temporarily paused while Starpharma and its UK distribution partner, LloydsPharmacy, addressed correspondence from the MHRA in relation to promotional claims.

Successful resolution of the queries raised follows the provision of extensive technical information on SPL7013 and VIRALEZE™ by Starpharma. Starpharma appreciates the detailed consideration of this matter by the MHRA. Following confirmation from the MHRA overnight, Starpharma will finalise the relaunch arrangements for the UK as soon as possible. Preparations for product supply are already underway.

In preparation for relaunch of VIRALEZE™ in the UK, Starpharma has been in discussions with LloydsPharmacy about the operational activities. The product is expected to be available both online and through LloydsPharmacy stores.

Dr Jackie Fairley, CEO of Starpharma, commented:

> *"We are delighted to be relaunching VIRALEZE™ in the UK. We look forward to making VIRALEZE™ available to UK consumers again very soon. VIRALEZE™ is registered in more than 30 countries, and we look forward to rolling the product out into further markets this year."*

VIRALEZE™ is registered as a medical device in the UK and carries a CE mark.

VIRALEZE™ Antiviral Nasal Spray

VIRALEZE™ is a broad-spectrum antiviral nasal spray. The antiviral agent in VIRALEZE™, referred to as SPL7013, has been shown to have potent antiviral and virucidal activity in multiple respiratory viruses (including influenza and RSV), including virucidal activity of more than 99% in multiple variants of SARS-CoV-2, in laboratory studies. VIRALEZE™ is applied in the nose to provide a physical barrier - between viruses and the nasal mucous membrane - that traps and blocks virus. Importantly, the mechanism of action of VIRALEZE™ means that mutations of the spike protein that make SARS-CoV-2 more infectious, as occurred for the Delta strain, appear to make the virus more susceptible to trapping and blocking by SPL7013.

VIRALEZE™ is now registered as a medical device in more than 30 countries, including in Europe, Asia, and the Middle East, and available in certain markets online. Product claims may differ by market. VIRALEZE™ is partnered with LloydsPharmacy in the UK, ADMENTA Italia Group in Italy, HealthCo/TBL in Vietnam, and E&N in countries in the Middle East. VIRALEZE™ is not approved for sale or supply in Australia.

VIRALEZE™ was developed with the support of $1 million in funding by the Australian Government's Medical Research Future Fund (MRFF) Biomedical Translation Bridge (BTB) Program, with support from UniQuest.

About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for respiratory viruses, DEP® drug delivery and VivaGel®. Starpharma has developed VIRALEZE™, an antiviral nasal spray that is registered for sale in >30 countries, including in Europe, Asia, and the Middle East, and available outside Australia in certain markets online. VIRALEZE™ is not approved for sale or supply in Australia. SPL7013 is utilised in approved products - the VivaGel® condom and VivaGel® BV. VivaGel® products have been licensed in >160 countries, are registered in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, South Africa, Australia and New Zealand.

As a leading company in dendrimer-based drug delivery, Starpharma's proprietary drug delivery platform technology, DEP®, is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP® versions of existing drugs, particularly in the area of anti-cancer therapies. DEP® partnerships include oncology programs with AstraZeneca, with Merck in the area of Antibody Drug Conjugates (ADCs), with Chase Sun in the area of anti-infectives and other world leading pharmaceutical companies. Starpharma's partnered DEP® programs have the potential to generate significant future milestones and royalties.

Starpharma.com | Twitter | LinkedIn

Media: Sumit Media
Grant Titmus
Mob: +61 419 388 161
grant@sumitmedia.com.au

Starpharma Holdings Limited
Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067

Disclosure
This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.